Your browser doesn't support javascript.
loading
Increasing of New CA-MRSA Infections Detected in people living with HIV Who Engage in Chemsex in Barcelona: An Ambispective Study.
De La Mora, Lorena; Pitart, Cristina; Morata, Laura; Ugarte, Ainoa; Martinez-Rebollar, María; De Lazzari, Elisa; Vergara, Andrea; Bosch, Jordi; Roca, Ignasi; Piquet, Maria; Rodriguez, Ana; Laguno, Montserrat; Ambrosioni, Juan; Torres, Berta; González-Cordón, Ana; Inciarte, Alexy; Foncillas, Alberto; Riera, Josep; Fuertes, Irene; Chivite, Iván; Martinez, Esteban; Blanco, José L; Soriano, Alex; Mallolas, Josep.
Afiliação
  • De La Mora L; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Pitart C; Department of Clinical Microbiology, ISGlobal, Hospital Clínic-University of Barcelona, CIBERINF, Barcelona, Spain.
  • Morata L; Department of Infectious Diseases, Hospital Clinic, IDIBAPS, CIBERINF, University of Barcelona, Barcelona, Spain.
  • Ugarte A; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Martinez-Rebollar M; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. rebollar@clinic.cat.
  • De Lazzari E; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Vergara A; Department of Clinical Microbiology, ISGlobal, Hospital Clínic-University of Barcelona, CIBERINF, Barcelona, Spain.
  • Bosch J; Department of Clinical Microbiology, ISGlobal, Hospital Clínic-University of Barcelona, CIBERINF, Barcelona, Spain.
  • Roca I; Department of Clinical Microbiology, ISGlobal, Hospital Clínic-University of Barcelona, CIBERINF, Barcelona, Spain.
  • Piquet M; Department of Clinical Microbiology, ISGlobal, Hospital Clínic-University of Barcelona, CIBERINF, Barcelona, Spain.
  • Rodriguez A; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Laguno M; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Ambrosioni J; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Torres B; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • González-Cordón A; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Inciarte A; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Foncillas A; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Riera J; Dermatology Service, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Fuertes I; Dermatology Service, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Chivite I; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Martinez E; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Blanco JL; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
  • Soriano A; Department of Infectious Diseases, Hospital Clinic, IDIBAPS, CIBERINF, University of Barcelona, Barcelona, Spain.
  • Mallolas J; HIV Unit, Infectious Diseases Service, Hospital Clinic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Infect Dis Ther ; 12(8): 2179-2189, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37491688
ABSTRACT

INTRODUCTION:

There are no data on community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections in the context of the chemsex phenomenon. This study aimed to characterize CA-MRSA-related infections in a cohort of people living with HIV (PLWH) who engage in chemsex.

METHODS:

At the Hospital Clinic of Barcelona, from February 2018 to January 2022, we analyzed CA-MRSA infections diagnosed in a cohort of PLWH who engage in chemsex. Epidemiological, behavioral and clinical variables were assessed. Mass spectrometry identification and antimicrobial susceptibility testing were performed on MRSA isolates. Pulse field electrophoresis was used to assess the clonality of the MRSA strains. The presence of Panton-Valentine leukocidin was also investigated.

RESULTS:

Among the cohort of 299 participants who engage in chemsex, 25 (8%) with CA-MRSA infections were identified, 9 at baseline and 16 with incident cases; the cumulative incidence was 5.5% (95% CI 3.2%, 8.8%). The most common drugs were methamphetamine (96%) and GHB/GBL (92%). Poly-consumption and slamming were reported by 32% and 46%, respectively. CA-MRSA was isolated from the infection sites of 20 participants, and CA-MRSA colonization was confirmed in the remaining 5 persons. Seventy-one percent had used antibiotics in the previous year. All participants presented with skin and soft tissue infections, 28% required hospitalization, and 48% had recurrence. Of the 23 MRSA isolates further studied, 19 (82,6%) belonged to the same clone. Panton-Valentine leukocidin was detected in all isolates.

CONCLUSION:

PLWH who engage in chemsex may present with CA-MRSA infections. Clinical suspicion and microbiological diagnosis are required to provide adequate therapy, and CA-MRSA prevention interventions should be designed.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article